Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Keyi Yang -- 1165 2022-04-06 07:42:24 |
2 Adjust the reference format Lindsay Dong Meta information modification 1165 2022-04-06 11:48:46 | |
3 none. Zhunzhun Liu Meta information modification 1165 2022-04-08 12:31:37 | |
4 Adding me as co-author Daniela Doege Meta information modification 1165 2022-04-08 12:42:01 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Yang, K.; , .; Thong, M.; Arndt, V.; Liu, Z.; Doege, D. Incidence of Diabetes in Cancer Patients. Encyclopedia. Available online: https://encyclopedia.pub/entry/21381 (accessed on 07 February 2026).
Yang K,  , Thong M, Arndt V, Liu Z, Doege D. Incidence of Diabetes in Cancer Patients. Encyclopedia. Available at: https://encyclopedia.pub/entry/21381. Accessed February 07, 2026.
Yang, Keyi, , Melissa Thong, Volker Arndt, Zhunzhun Liu, Daniela Doege. "Incidence of Diabetes in Cancer Patients" Encyclopedia, https://encyclopedia.pub/entry/21381 (accessed February 07, 2026).
Yang, K., , ., Thong, M., Arndt, V., Liu, Z., & Doege, D. (2022, April 06). Incidence of Diabetes in Cancer Patients. In Encyclopedia. https://encyclopedia.pub/entry/21381
Yang, Keyi, et al. "Incidence of Diabetes in Cancer Patients." Encyclopedia. Web. 06 April, 2022.
Incidence of Diabetes in Cancer Patients
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers14071808

Diabetes increases the risk of certain types of cancer. Meanwhile, new-onset diabetes is positively associated with cancer, but this association varies according to cancer type. 

Cancer Patients Cancer Survivors Incidence of Diabetes

1. Introduction

Cancer today is considered a major public health problem globally. It is estimated that around 19.3 million new cancer cases were diagnosed in 2020 worldwide [1]. Due to improvements in cancer screening, diagnosis, and therapy as well as demographic aging [2][3][4], the number of cancer patients (including long-term cancer survivors who have survived for at least 5 years [5]) is increasing worldwide [6].
Comorbid diabetes among cancer patients could be common [7]. Diabetes is found to be more prevalent in cancer patients than in the cancer-free population [8] which may be due to several reasons. For instance, cancer and comorbid diabetes could share common risk factors, such as older age, smoking, obesity, unhealthy diet, physical inactivity, and higher alcohol consumption [9]. Diabetes might also increase the risk for certain types of cancer such as breast cancer and colorectal cancer, and doubles the risk of liver, pancreas, and endometrial cancer [10]. In addition to the cancer disease, cancer treatments such as radiotherapy, glucocorticoids, targeted therapy, hematopoietic cell transplantation (HCT), and androgen deprivation therapy (ADT) may also result in an increased risk for diabetes [11][12][13][14][15][16][17][18][19].
In cancer patients, diabetes is associated with a poorer health-related quality of life (HRQOL) [20], higher healthcare utilization [21], and an increased risk of cancer progression and mortality [22][23][24], which highlights the clinical importance of knowing whether cancer patients are more likely to develop diabetes.

2. Incidence of Diabetes in Cancer Patients

The incidence of new-onset diabetes in general was higher in cancer patients compared with the cancer-free population. Although there is currently no clear explanation on the underlying mechanism for the association between cancer and diabetes, there are still some clues to be tracked. According to previous studies, most cancer treatment modalities could be positively associated with new-onset diabetes. When our body is not able to produce sufficient insulin or cannot use it effectively, diabetes occurs [25]. Interestingly, varying mechanisms for diabetes can be observed in different therapeutic methods according to cancer type. Surgery and radiotherapy involving the pancreas can result in pancreatic insufficiency, which is one of the important reasons for diabetes development [12]. Cranial irradiation and total body irradiation can influence the hypothalamic–pituitary axis, leading to changes in the body composition (e.g., overweight) and insulin resistance [13][14]. Although no evidence has been found that chemotherapeutic drugs could directly impinge on glucose metabolism, in classical chemotherapy regimens, they are often used in conjunction with glucocorticoids. Glucocorticoids can enhance the efficacy of chemotherapy, treat swelling, intracranial hypertension, pain, nausea, or be used as antitumor drugs in hematological malignancies [15]. Glucocorticoids affect several insulin-signaling pathways, leading to reduced insulin sensitivity, inducing insulin resistance, and increasing the risk of diabetes [15]. Targeted therapy drugs are also often used alone or in combination with chemotherapy. Some inhibitors block the pathways that are also involved in glucose regulation, such as the tyrosine kinase receptors insulin growth factor receptor 1 (IGF-1R) which could lead to insulin resistance [16]. Patients with hematologic malignancies are at high risk of exposure to glucocorticoids. They are also likely to receive HCT. HCT can contribute to the release of several proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) [17][18], and previous studies have shown that the latter could contribute to insulin resistance by influencing the insulin signaling pathway [19]. ADT is widely used in prostate cancer [26]. A reduction in testosterone levels can be observed during the application of ADT drugs, however, decreased testosterone is directly associated with insulin resistance in men [27]. As for hormone therapy for breast cancer patients, it observed no significant association in a subgroup analysis involving only patients having received hormone therapy. This might be due to the favorable changes on the lipid profile by aromatase inhibitors (AIs) and tamoxifen [28][29].

The incidence of diabetes may be higher in the first year after cancer diagnosis. Closer contact between care providers and patients and a potential higher risk of detection bias in the initial years after cancer diagnosis might be possible explanations for this observation. Furthermore, some limitations in the underlying studies such as information bias regarding the correct assessment of the timing of the diabetes diagnosis and the potential survival bias during long-term follow-up could also explain these results. Moreover, since there is an age-related increase in diabetes risk in both cancer patients and controls [30], a reduced relative risk might be observed with the passing of time.

However, a statistically significant positive association was also observed during years one to ten. Several reasons could partly explain the fact that incident diabetes was still positively associated with cancer five or more years post diagnosis, when the effects of most treatments would most likely have subsided. First, in cancer patients, particularly those who suffer from cancer cachexia, insulin resistance often occurs as a result of the secretion and activation of several proinflammatory cytokines induced by cancer itself, such as TNF-α [31][32][33]. Some psychological consequences of cancer, such as depression, may also make the survivors more vulnerable to diabetes due to integrated mechanisms such as hypothalamic abnormality and an unhealthy lifestyle [34]. Moreover, the alteration of the glucose metabolism can start to appear more than ten years before the diagnosis of diabetes [35]. Furthermore, cancer and diabetes share a number of common risk factors, such as obesity, tobacco abuse, and alcohol consumption [9] and cancer survivors are more likely to be physically inactive compared with the general population [36]. A positive association was also observed ten or more years post diagnosis. Although this result was not statistically significant, the potential positive association should not be ignored, and future studies with sufficient power and a sufficiently long follow-up post cancer diagnosis are recommended. Furthermore, extension of surveillance for incident diabetes to beyond ten years post diagnosis could be of clinical relevance.

The association between cancer and new-onset diabetes varied by cancer type. The highest relative risk of diabetes was found in pancreatic cancer, which was not surprising. This association in patients of hematologic malignancies was also strong, which was comparable with another study [37], possibly due to intensive and comprehensive therapy such as total body irradiation, chemotherapy with glucocorticoids, and HCT. However, there is a statistically significant inverse association in the head and neck cancer patients. One possible explanation could be that cancer patients whose salivary glands and oral cavity were included in the treatment field, whether surgery or radiotherapy, could experience an unpleasant dietary intake thus would be less likely to become obese [38]. Furthermore, increased glucose-disposal rates were found in head and neck cancer patients indicating that the cancer cells played the role of a glucose drain [39].

In summary, new-onset diabetes was positively associated with cancer. This association was stronger during the first years after cancer diagnosis and varied according to cancer type. In this context, integration and coordination of healthcare should be applied for cancer patients. More prospective studies with large sample sizes and longer follow-up times (over ten years post diagnosis) are advocated to further examine the association and the underlying mechanisms.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  2. Derksen, J.W.G.; Beijer, S.; Koopman, M.; Verkooijen, H.M.; van de Poll-Franse, L.V.; May, A.M. Monitoring potentially modifiable lifestyle factors in cancer survivors: A narrative review on currently available methodologies and innovations for large-scale surveillance. Eur. J. Cancer 2018, 103, 327–340.
  3. Malvezzi, M.; Bertuccio, P.; Rosso, T.; Rota, M.; Levi, F.; La Vecchia, C.; Negri, E. European cancer mortality predictions for the year 2015: Does lung cancer have the highest death rate in EU women. Ann. Oncol. 2015, 26, 779–786.
  4. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33.
  5. Aziz, N.M. Cancer survivorship research: State of knowledge, challenges and opportunities. Acta Oncol. 2007, 46, 417–432.
  6. Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M.; Nikšić, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; et al. Global surveillance of trends in cancer survival 2000–2014 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018, 391, 1023–1075.
  7. Edwards, B.K.; Noone, A.-M.; Mariotto, A.B.; Simard, E.P.; Boscoe, F.P.; Henley, S.J.; Jemal, A.; Cho, H.; Anderson, R.N.; Kohler, B.A.; et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014, 120, 1290–1314.
  8. Chen, S.S.; Nadarajah, A.; Wang, K.-W.; Kay, S.; Banfield, L.; Foroutan, F.; Johnston, D.; Zelcer, S.; Rassekh, S.R.; Thabane, L.; et al. The Prevalence of Diabetes Mellitus in Childhood Cancer Survivors: A Systematic Review and Meta-Analysis. Can. J. Diabetes 2020, 44, S19.
  9. Extermann, M. Interaction between comorbidity and cancer. Cancer Control 2007, 14, 13–22.
  10. Giovannucci, E.; Harlan, D.M.; Archer, M.C.; Bergenstal, R.M.; Gapstur, S.M.; Habel, L.A.; Pollak, M.; Regensteiner, J.G.; Yee, D. Diabetes and cancer: A consensus report. Diabetes Care 2010, 33, 1674–1685.
  11. Wang, H.; Sun, X.; Zhao, L.; Chen, X.; Zhao, J. Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis. J. Diabetes Investig. 2016, 7, 629–636.
  12. De Vathaire, F.; El-Fayech, C.; Ben Ayed, F.F.; Haddy, N.; Guibout, C.; Winter, D.; Thomas-Teinturier, C.; Veres, C.; Jackson, A.; Pacquement, H.; et al. Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: A retrospective cohort study. Lancet Oncol. 2012, 13, 1002–1010.
  13. Friedman, D.N.; Tonorezos, E.S.; Cohen, P. Diabetes and Metabolic Syndrome in Survivors of Childhood Cancer. Horm. Res. Paediatr. 2019, 91, 118–127.
  14. Sklar, C.A.; Mertens, A.C.; Walter, A.; Mitchell, D.; Nesbit, M.E.; O’Leary, M.; Hutchinson, R.; Meadows, A.T.; Robison, L.L. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: Role of cranial irradiation. Med. Pediatr. Oncol. 2000, 35, 91–95.
  15. Ariaans, G.; de Jong, S.; Gietema, J.A.; Lefrandt, J.D.; de Vries, E.G.E.; Jalving, M. Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect. Cancer Treat. Rev. 2015, 41, 376–384.
  16. Goldman, J.W.; Mendenhall, M.A.; Rettinger, S.R. Hyperglycemia Associated with Targeted Oncologic Treatment: Mechanisms and Management. Oncologist 2016, 21, 1326–1336.
  17. Sakata, N.; Yasui, M.; Okamura, T.; Inoue, M.; Yumura-Yagi, K.; Kawa, K. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: The ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant. 2001, 27, 1153–1161.
  18. Schots, R.; Kaufman, L.; van Riet, I.; Ben Othman, T.; de Waele, M.; van Camp, B.; Demanet, C. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003, 17, 1150–1156.
  19. Hotamisligil, G.S. Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes 1999, 107, 119–125.
  20. Thong, M.S.Y.; van de Poll-Franse, L.; Hoffman, R.M.; Albertsen, P.C.; Hamilton, A.S.; Stanford, J.L.; Penson, D.F. Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int. 2011, 107, 1223–1231.
  21. Zylla, D.; Gilmore, G.; Eklund, J.; Richter, S.; Carlson, A. Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. J. Diabetes Complicat. 2019, 33, 335–339.
  22. Brown, J.C.; Zhang, S.; Ou, F.-S.; Venook, A.P.; Niedzwiecki, D.; Lenz, H.-J.; Innocenti, F.; O’Neil, B.H.; Shaw, J.E.; Polite, B.N.; et al. Diabetes and Clinical Outcome in Patients with Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectr. 2020, 4, pkz078.
  23. Ederaine, S.A.; Dominguez, J.L.; Harvey, J.A.; Mangold, A.R.; Cook, C.B.; Kosiorek, H.; Buras, M.; Coppola, K.; Karlin, N.J. Survival and glycemic control in patients with co-existing squamous cell carcinoma and diabetes mellitus. Future Sci. OA 2021, 7, FSO683.
  24. Zhao, X.-B.; Ren, G.-S. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine 2016, 95, e5602.
  25. International Diabetes Federation. IDF Diabetes Atlas, 9th ed.; International Diabetes Federation: Brussels, Belgium, 2019.
  26. Basaria, S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. J. Androl. 2008, 29, 534–539.
  27. Pitteloud, N.; Hardin, M.; Dwyer, A.A.; Valassi, E.; Yialamas, M.; Elahi, D.; Hayes, F.J. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J. Clin. Endocrinol. Metab. 2005, 90, 2636–2641.
  28. Santorelli, M.L.; Hirshfield, K.M.; Steinberg, M.B.; Rhoads, G.G.; Lin, Y.; Demissie, K. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women. Ann. Epidemiol. 2016, 26, 436–440.
  29. Ng, H.S.; Koczwara, B.; Roder, D.M.; Niyonsenga, T.; Vitry, A.I. Comorbidities in Australian women with hormone-dependent breast cancer: A population-based analysis. Med. J. Aust. 2018, 208, 24–28.
  30. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 2019, 157, 107843.
  31. Fearon, K.C.H.; Glass, D.J.; Guttridge, D.C. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16, 153–166.
  32. Porporato, P.E. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis 2016, 5, e200.
  33. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Investig. 2006, 116, 1793–1801.
  34. Yu, M.; Zhang, X.; Lu, F.; Fang, L. Depression and Risk for Diabetes: A Meta-Analysis. Can. J. Diabetes 2015, 39, 266–272.
  35. Tabák, A.G.; Jokela, M.; Akbaraly, T.N.; Brunner, E.J.; Kivimäki, M.; Witte, D.R. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet 2009, 373, 2215–2221.
  36. Hawkins, M.L.; Buys, S.S.; Gren, L.H.; Simonsen, S.E.; Kirchhoff, A.C.; Hashibe, M. Do cancer survivors develop healthier lifestyle behaviors than the cancer-free population in the PLCO study. J. Cancer Surviv. 2017, 11, 233–245.
  37. Jung, H.-S.; Myung, S.-K.; Kim, B.-S.; Seo, H.G. Metabolic syndrome in adult cancer survivors: A meta-analysis. Diabetes Res. Clin. Pract. 2012, 95, 275–282.
  38. Munshi, A.; Pandey, M.B.; Durga, T.; Pandey, K.C.; Bahadur, S.; Mohanti, B.K. Weight loss during radiotherapy for head and neck malignancies: What factors impact it. Nutr. Cancer 2003, 47, 136–140.
  39. Byerley, L.O.; Heber, D.; Bergman, R.N.; Dubria, M.; Chi, J. Insulin action and metabolism in patients with head and neck cancer. Cancer 1991, 67, 2900–2906.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Keyi Yang ,
, Melissa Thong , Volker Arndt , Zhunzhun Liu , Daniela Doege
View Times: 797
Revisions: 4 times (View History)
Update Date: 08 Apr 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback